Cargando…
The Effects of Atorvastatin on Arterial Stiffness in Male Patients with Type 2 Diabetes
Statin therapy improves lipid profiles and reduces vascular inflammation, but its effects on central arterial stiffness in type 2 diabetes are unclear. The aim of this study was to determine whether statin therapy reduces central arterial stiffness, in a dose-dependent manner, in male patients with...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430667/ https://www.ncbi.nlm.nih.gov/pubmed/26064990 http://dx.doi.org/10.1155/2015/846807 |
_version_ | 1782371215677063168 |
---|---|
author | Davenport, Colin Ashley, David T. O'Sullivan, Eoin P. McHenry, Claire M. Agha, Amar Thompson, Christopher J. O'Gorman, Donal J. Smith, Diarmuid |
author_facet | Davenport, Colin Ashley, David T. O'Sullivan, Eoin P. McHenry, Claire M. Agha, Amar Thompson, Christopher J. O'Gorman, Donal J. Smith, Diarmuid |
author_sort | Davenport, Colin |
collection | PubMed |
description | Statin therapy improves lipid profiles and reduces vascular inflammation, but its effects on central arterial stiffness in type 2 diabetes are unclear. The aim of this study was to determine whether statin therapy reduces central arterial stiffness, in a dose-dependent manner, in male patients with type 2 diabetes. Fifty-one patients ceased statin therapy for 6 weeks, followed by randomisation to either 10 or 80 mg of atorvastatin. At randomization, 3 and 12 months, central arterial stiffness was measured via carotid-femoral pulse wave velocity (PWV), along with serum markers of vascular inflammation including high-sensitivity c-reactive protein (hsCRP) and osteoprotegerin (OPG). PWV decreased from 10.37 ± 1.30 to 9.68 ± 1.19 m/sec (p < 0.01 from baseline) at 3 months and 9.10 ± 1.17 m/sec (p < 0.001 from baseline) at 12 months. hsCRP and OPG decreased significantly at 3 and 12 months. Reductions in PWV did not differ significantly between the groups. Baseline PWV and OPG values correlated strongly (r = 0.48, p < 0.01), as did their response to atorvastatin over 12 months (r = 0.36 delta-OPG and delta-PWV, p < 0.01). Atorvastatin therapy appeared to reduce central arterial stiffness in male type 2 diabetes, with no dose-dependent effect observed. The correlation observed between reductions in PWV and OPG suggests that atorvastatin reduces PWV via direct anti-inflammatory effects on the vasculature. |
format | Online Article Text |
id | pubmed-4430667 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-44306672015-06-10 The Effects of Atorvastatin on Arterial Stiffness in Male Patients with Type 2 Diabetes Davenport, Colin Ashley, David T. O'Sullivan, Eoin P. McHenry, Claire M. Agha, Amar Thompson, Christopher J. O'Gorman, Donal J. Smith, Diarmuid J Diabetes Res Research Article Statin therapy improves lipid profiles and reduces vascular inflammation, but its effects on central arterial stiffness in type 2 diabetes are unclear. The aim of this study was to determine whether statin therapy reduces central arterial stiffness, in a dose-dependent manner, in male patients with type 2 diabetes. Fifty-one patients ceased statin therapy for 6 weeks, followed by randomisation to either 10 or 80 mg of atorvastatin. At randomization, 3 and 12 months, central arterial stiffness was measured via carotid-femoral pulse wave velocity (PWV), along with serum markers of vascular inflammation including high-sensitivity c-reactive protein (hsCRP) and osteoprotegerin (OPG). PWV decreased from 10.37 ± 1.30 to 9.68 ± 1.19 m/sec (p < 0.01 from baseline) at 3 months and 9.10 ± 1.17 m/sec (p < 0.001 from baseline) at 12 months. hsCRP and OPG decreased significantly at 3 and 12 months. Reductions in PWV did not differ significantly between the groups. Baseline PWV and OPG values correlated strongly (r = 0.48, p < 0.01), as did their response to atorvastatin over 12 months (r = 0.36 delta-OPG and delta-PWV, p < 0.01). Atorvastatin therapy appeared to reduce central arterial stiffness in male type 2 diabetes, with no dose-dependent effect observed. The correlation observed between reductions in PWV and OPG suggests that atorvastatin reduces PWV via direct anti-inflammatory effects on the vasculature. Hindawi Publishing Corporation 2015 2015-04-30 /pmc/articles/PMC4430667/ /pubmed/26064990 http://dx.doi.org/10.1155/2015/846807 Text en Copyright © 2015 Colin Davenport et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Davenport, Colin Ashley, David T. O'Sullivan, Eoin P. McHenry, Claire M. Agha, Amar Thompson, Christopher J. O'Gorman, Donal J. Smith, Diarmuid The Effects of Atorvastatin on Arterial Stiffness in Male Patients with Type 2 Diabetes |
title | The Effects of Atorvastatin on Arterial Stiffness in Male Patients with Type 2 Diabetes |
title_full | The Effects of Atorvastatin on Arterial Stiffness in Male Patients with Type 2 Diabetes |
title_fullStr | The Effects of Atorvastatin on Arterial Stiffness in Male Patients with Type 2 Diabetes |
title_full_unstemmed | The Effects of Atorvastatin on Arterial Stiffness in Male Patients with Type 2 Diabetes |
title_short | The Effects of Atorvastatin on Arterial Stiffness in Male Patients with Type 2 Diabetes |
title_sort | effects of atorvastatin on arterial stiffness in male patients with type 2 diabetes |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430667/ https://www.ncbi.nlm.nih.gov/pubmed/26064990 http://dx.doi.org/10.1155/2015/846807 |
work_keys_str_mv | AT davenportcolin theeffectsofatorvastatinonarterialstiffnessinmalepatientswithtype2diabetes AT ashleydavidt theeffectsofatorvastatinonarterialstiffnessinmalepatientswithtype2diabetes AT osullivaneoinp theeffectsofatorvastatinonarterialstiffnessinmalepatientswithtype2diabetes AT mchenryclairem theeffectsofatorvastatinonarterialstiffnessinmalepatientswithtype2diabetes AT aghaamar theeffectsofatorvastatinonarterialstiffnessinmalepatientswithtype2diabetes AT thompsonchristopherj theeffectsofatorvastatinonarterialstiffnessinmalepatientswithtype2diabetes AT ogormandonalj theeffectsofatorvastatinonarterialstiffnessinmalepatientswithtype2diabetes AT smithdiarmuid theeffectsofatorvastatinonarterialstiffnessinmalepatientswithtype2diabetes AT davenportcolin effectsofatorvastatinonarterialstiffnessinmalepatientswithtype2diabetes AT ashleydavidt effectsofatorvastatinonarterialstiffnessinmalepatientswithtype2diabetes AT osullivaneoinp effectsofatorvastatinonarterialstiffnessinmalepatientswithtype2diabetes AT mchenryclairem effectsofatorvastatinonarterialstiffnessinmalepatientswithtype2diabetes AT aghaamar effectsofatorvastatinonarterialstiffnessinmalepatientswithtype2diabetes AT thompsonchristopherj effectsofatorvastatinonarterialstiffnessinmalepatientswithtype2diabetes AT ogormandonalj effectsofatorvastatinonarterialstiffnessinmalepatientswithtype2diabetes AT smithdiarmuid effectsofatorvastatinonarterialstiffnessinmalepatientswithtype2diabetes |